Company intelligence / Profile preview

TauRx Therapeutics Ltd

Singapore, Singaporetaurx.com ↗

Ownership: Private
Employees: ~100
Development stage: Phase 3

Overview

TauRx has completed Phase 3 clinical trials (LUCIDITY) for its lead compound hydromethylthionine mesylate (HMTM), showing positive results. The company has submitted its first product for approval to the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for mild cognitive impairment and mild to moderate Alzheimer's disease. Previous Phase 3 trials showed pharmacological activity on clinical decline and brain atrophy.

Therapeutic areas: Neurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

hydromethylthionine mesylate

3 more assets in the full pipeline.

Partnerships

Genting TauRx Diagnostics Ltd (GTD) - joint venture

Beyond the preview

Go deeper on TauRx Therapeutics Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TauRx Therapeutics Ltd.